ArticleNature biotechnology2024
A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection.
Open access · greenAbstract read
In one paragraph
Article in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- The emerging role of microbiota in neuro-oncology.Nature reviews. Neurology · 2026Review
- Insights into Microbiota-Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons.Vaccines · 2026Review
- HIV cure after HCT: 7 horses seem to be on the mark.Blood advances · 2026Article
- The microbiota-gut-immunity axis in teleost fish: dual regulatory mechanisms of viral infections and prospects for microbiome-based antiviral strategies.Fish physiology and biochemistry · 2026Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- The microbiome-EBV axis in carcinogenesis bridges commensal influence and viral oncogenesis.Frontiers in immunology · 2026Review
- SARS-CoV-2 infection induces pro-fibrotic and pro-thrombotic foam cell formation.Nature microbiology · 2025Article
- Envelope-dimer epitope 1 (EDE1) antibody (C10) treatment significantly reduces Zika virus replication in the male and female reproductive tracts.Journal of virology · 2025Article
- The promise and perils of humanized mice: workshop report from the 29th scientific conference of the society on NeuroImmune pharmacology (SNIP).NeuroImmune pharmacology and therapeutics · 2025Article
- Article
- Stunting is associated with persistent and transferable alterations in the gut microbiome.Gut pathogens · 2025Article
- A single mutation in an enteric virus alters tropism and sensitivity to microbiota.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- T Cell Development and Responses in Human Immune System Mice.Annual review of immunology · 2025Review
- Alcohol Use Disorder and the Gut-Brain Axis: A Narrative Review of the Role of Gut Microbiota and Implications for Treatment.Microorganisms · 2025Review
- HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies.Frontiers in immunology · 2025Review
- The oral-gut microbiome axis in health and disease.Nature reviews. Microbiology · 2024Review
- Exploring potential associations between the human microbiota and reservoir of latent HIV.Retrovirology · 2024Review
- Gastrointestinal Microbiota in Gastric Cancer: Potential Mechanisms and Clinical Applications-A Literature Review.Cancers · 2024Review
- A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.Signal transduction and targeted therapy · 2024Review
- Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 3 countries.
Angela Wahl *International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. awahl@med.unc.edu.
Wenbo Yao *International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8488-4450
Baolin Liao *International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Morgan ChateauInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cara RichardsonInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lijun LingInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Adrienne FranksInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Krithika SenthilInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Genevieve DoyonInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Fengling LiCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Josh FrostCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Christopher B WhitehurstDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, USA.
Joseph S PaganoDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Craig A FletcherDivision of Comparative Medicine, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
M Andrea Azcarate-PerilCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael G HudgensDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Allison R RogalaCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joseph D TuckerDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ian McGowanDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, USA.
R Balfour SartorCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
J Victor GarciaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victor_garcia@med.unc.edu.ORCID http://orcid.org/0000-0003-3726-0482
University of North Carolina at Chapel Hill · USNew York Medical College · USUniversity of Pittsburgh · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MUNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Venkata Saroja Voruganti · 1999 to 2026
$31.6MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6MPILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MRole of IL-10 in APC Regulation of Protective vs. Pathogenic T Cell Responses toP01DK094779 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SARTOR, RYAN B · 2013 to 2023
$17.9MTopical Antiretrovirals to Prevent Rectal HIV InfectionU19AI082637 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI ROHAN, LISA CENCIA · 2009 to 2013
$11.1MNational Gnotobiotic Rodent Resource CenterP40OD010995 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ryan B Sartor · 2012 to 2026
$9.7MThe Role of Human Gut Microbiota in HIV-1 Rectal Acquisition, Replication, and PathogenesisR01AI123010 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WAHL, ANGELA RAQUEL · 2016 to 2020
$3.7MImpact of the gastrointestinal microbiome on HIV reservoirsR01DK131585 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI J. Victor Garcia-Martinez, Ryan B Sartor · 2021 to 2026
$3.4MMentoring Multidisciplinary Global HIV Patient-Oriented ResearchK24AI143471 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph David Tucker · 2019 to 2026
$1.4MFIC NIH HHS D43 TW009532NCI NIH HHS P30 CA016086NIAID NIH HHS K24 AI143471NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI123010NIAID NIH HHS U19 AI082637NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164567NIDDK NIH HHS P01 DK094779NIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK131585NIH HHS P40 OD010995NIMH NIH HHS R34 MH119963U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1UM1AI126619U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI123010U.S. Department of Health & Human Services | National Institutes of Health (NIH) DK131585U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30DK034987U.S. Department of Health & Human Services | National Institutes of Health (NIH) P40OD010995U.S. Department of Health & Human Services | National Institutes of Health (NIH) U19AI082637U.S. Department of Health & Human Services | NIH | Fogarty International Center (FIC) D43TW009532
Abstract
Germ-free (GF) mice, which are depleted of their resident microbiota, are the gold standard for exploring the role of the microbiome in health and disease; however, they are of limited value in the study of human-specific pathogens because they do not support their replication. Here, we develop GF mice systemically reconstituted with human immune cells and use them to evaluate the role of the resident microbiome in the acquisition, replication and pathogenesis of two human-specific pathogens, Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV). Comparison with conventional (CV) humanized mice showed that resident microbiota enhance the establishment of EBV infection and EBV-induced tumorigenesis and increase mucosal HIV acquisition and replication. HIV RNA levels were higher in plasma and tissues of CV humanized mice compared with GF humanized mice. The frequency of CCR5
Indexed as
Disease Models, AnimalGerm-Free LifeHIV InfectionsMicrobiotaAnimalsCD4-Positive T-LymphocytesEpstein-Barr Virus InfectionsGastrointestinal MicrobiomeHerpesvirus 4, HumanHIVHumansMice
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.